2.99
-0.09(-2.92%)
Currency In USD
| Previous Close | 3.08 |
| Open | 3.08 |
| Day High | 3.1 |
| Day Low | 2.93 |
| 52-Week High | 13.65 |
| 52-Week Low | 2.87 |
| Volume | 69,967 |
| Average Volume | 112,361 |
| Market Cap | 13.28M |
| PE | -0.31 |
| EPS | -9.73 |
| Moving Average 50 Days | 6.48 |
| Moving Average 200 Days | 7.89 |
| Change | -0.09 |
If you invested $1000 in Tempest Therapeutics, Inc. (TPST) 10 years ago, it would be worth $1.35 as of December 27, 2025 at a share price of $2.99. Whereas If you bought $1000 worth of Tempest Therapeutics, Inc. (TPST) shares 5 years ago, it would be worth $92.71 as of December 27, 2025 at a share price of $2.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc.
Nov 26, 2025 9:05 PM GMT
$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrantsBRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: T
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc.
Nov 25, 2025 1:00 PM GMT
$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrantsBRISBANE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: T
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027
GlobeNewswire Inc.
Nov 19, 2025 2:00 PM GMT
All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T programAcquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR⍺ Antagonist, Phase 3-ready) and TPST-1495 (Dual Ep2/4 Antagonist, Phase 2 start expected ne